The company is still reeling from the impact of expenses related to litigation, additional DePuy ASR Hip recall costs and the recent acquisition of Synthes. The company spent $233 million on litigation and recall expenses.
Read the financial report for DePuy Orthopaedics.
Related Articles to DePuy:
DePuy Orthopaedics’ Foot and Hip System Receive FDA 510(k) Clearance
DePuy Orthopaedics Names Andrew Ekdahl President
DePuy’s New Ceramic-on-Metal Hip Implant Receives FDA Clearance
